Note 8 - Segment Reporting - Summary of Operating Results by Reportable Segments (Details) - USD ($)	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Net revenues	$ 3,069,000	$ 3,767,000
Cost of revenues	2,138,000	2,385,000
Gross profit	931,000	1,382,000
Operating expenses	3,281,000	3,330,000
Operating loss	(2,350,000)	(1,948,000)
Depreciation and amortization	160,000	261,000
Stock-based compensation expense	132,000	298,000
Operating profit (loss)	(2,350,000)	(1,948,000)
Intersegment Eliminations [Member]
Net revenues	3,069,000	3,767,000
Cost of revenues	2,138,000	2,385,000
Gross profit	931,000	1,382,000
Operating expenses	3,281,000	3,330,000
Operating loss	(2,350,000)	(1,948,000)
Depreciation and amortization	160,000	261,000
Stock-based compensation expense	132,000	298,000
Operating profit (loss)	(2,350,000)	(1,948,000)
Clinical Development [Member] | Operating Segments [Member]
Net revenues	126,000
Cost of revenues	120,000
Gross profit	6,000
Operating expenses	1,169,000
Operating loss	(1,163,000)
Depreciation and amortization	75,000
Stock-based compensation expense	85,000
Operating profit (loss)	(1,163,000)
Clinical Protocols [Member] | Operating Segments [Member]
Net revenues		156,000
Cost of revenues		142,000
Gross profit		14,000
Operating expenses		1,964,000
Operating loss		(1,950,000)
Depreciation and amortization		139,000
Stock-based compensation expense		190,000
Operating profit (loss)		(1,950,000)
Device [Member] | Operating Segments [Member]
Net revenues	2,943,000
Cost of revenues	2,018,000
Gross profit	925,000
Operating expenses	2,112,000
Operating loss	(1,187,000)
Depreciation and amortization	85,000
Stock-based compensation expense	47,000
Operating profit (loss)	$ (1,187,000)
Device Registration [Member] | Operating Segments [Member]
Net revenues		3,611,000
Cost of revenues		2,243,000
Gross profit		1,368,000
Operating expenses		1,366,000
Operating loss		2,000
Depreciation and amortization		122,000
Stock-based compensation expense		108,000
Operating profit (loss)		$ 2,000